Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future
Michele Gottardi(Ca' Foncello Hospital), Claudio Cerchione(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Alessandra Sperotto(Istituto Oncologico Veneto), Delia Cangini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonella Padella(University of Bologna), Giovanni Martinelli(University of Bologna), Maria Benedetta Giannini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Andrea Ghelli Luserna di Rorà(Fondazione Pisa)
Cited by 18
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
|Blood|2011|460
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
|Journal of Clinical Oncology|2007|374